Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories

Targeted therapy (TT) has revolutionized cancer treatment, successfully applied in various settings. Adjuvant TT resected early-stage gastrointestinal stromal tumors (GIST), melanoma, non-small cell lung (NSCLC), and breast led to practice-changing achievements. In particular, standard treatments include BRAF inhibitors for osimertinib NSCLC, hormone or HER2 cancer, imatinib GIST. Despite the undeniable benefit derived from adjuvant TT, optimal duration of appropriate managing relapse remain open questions. Furthermore, neoadjuvant is emerging as valuable, particularly ongoing studies evaluate perioperative setting NSCLC. this review, we aim collect describe large amount data available literature about across different histologies, focusing on epidemiology, major advances, future directions.